Sattar, Naveed

Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2

Sattar, N., Verma, S., Sourij, H., Wilson, J., Stefanski, A., zhang, X., Griffin, R., Ruotolo, G., & Linetzky, B. (2024) · Circulation

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 10

Genetic evidence strongly supports managing weight and blood pressure in addition to glycemic control in preventing vascular complications in people with type 2 diabetes

Ahmed, A., Amin, H., Drenos, F., Sattar, N., & Yaghootkar, H. (2023) · Diabetes Care

Genetic Associations and EpidemiologyDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 10

Advancing a causal role of type 2 diabetes and its components in developing macro- and microvascular complications via genetic studies

Ahmed, A., Sattar, N., & Yaghootkar, H. (2022) · Diabetic Medicine

Genetic Associations and EpidemiologyDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 10

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure

Sattar, N., & Preiss, D. (2016) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 6

Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial

Zhyzhneuskaya, S. V., Al‐Mrabeh, A. H., Peters, C., Barnes, A. C., Hollingsworth, K. G., Welsh, P., Sattar, N., Lean, M. E. J., & Taylor, R. (2025) · Diabetic Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6

Shorter sleep: a new potential target to address cardiovascular and metabolic risk?

Boal, A. H., Gill, J. M. R., & Sattar, N. (2020) · Cardiovascular Research

Sleep and related disordersHealth disparities and outcomes

Cited by 5

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide

Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC

Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

Cited by 5

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis

Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 0